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Background: Despite high metastasis rates, adjuvant/neoadjuvant systemic therapy for localised soft tissue sarcoma (STS) is not
used routinely. Progress requires tailoring therapy to features of tumour biology, which need exploration in well-documented
cohorts. Hypoxia has been linked to metastasis in STS and is targetable. This study evaluated hypoxia prognostic markers in the
phase III adjuvant radiotherapy VorteX trial.
Methods: Formalin-fixed paraffin-embedded tumour biopsies, fresh tumour/normal tissue and blood were collected before
radiotherapy. Immunohistochemistry for HIF-1a, CAIX and GLUT1 was performed on tissue microarrays and assessed by two
scorers (one pathologist). Prognostic analysis of disease-free survival (DFS) used Kaplan–Meier and Cox regression.
Results: Biobank and outcome data were available for 203 out of 216 randomised patients. High CAIX expression was associated
with worse DFS (hazard ratio 2.28, 95% confidence interval: 1.44–3.59, Po0.001). Hypoxia-inducible factor-1a and GLUT1 were not
prognostic. Carbonic anhydrase IX remained prognostic in multivariable analysis.
Conclusions: The VorteX-Biobank contains tissue with linked outcome data and is an important resource for research. This study
confirms hypoxia is linked to poor prognosis in STS and suggests that CAIX may be the best known marker. However, overlap
between single marker positivity was poor and future work will develop an STS hypoxia gene signature to account for tumour
heterogeneity.
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Soft tissue sarcomas (STS) are cancers of mesenchymal origin that
are relatively rare, with B3000 cases per year diagnosed in adults
in the United Kingdom (Francis et al, 2013). They display
considerable heterogeneity; there are over 50 different malignant
histologic subtypes (Fletcher et al, 2013) and can occur in any
anatomical position (Clark et al, 2005). Most patients present with
localised disease that can be managed with curative intent. A
combination of surgery and radiotherapy results in high local
control rates (Zagars et al, 2003). However, high-risk patients (high
grade, deep, large tumours) have B50% 5-year survival (Weitz
et al, 2003). Most deaths are due to distant metastasis. The use of
chemotherapy in the adjuvant/neoadjuvant setting is controversial,
due to lack of a consistent overall survival benefit in clinical trials
(Pervaiz et al, 2008; Le Cesne et al, 2014). There is an important
unmet clinical need to explore new strategies to prevent metastatic
spread.
The failure of previous adjuvant/neoadjuvant trials may reflect
the molecular heterogeneity of the disease. Progress requires
identification of adverse features of tumour biology associated with
metastasis that can be targeted with novel systemic agents. VorteX
is a phase III randomised controlled trial assessing whether
reduced adjuvant radiotherapy volume can improve limb function
in adults with extremity STS. The VorteX-Biobank collected a
range of tissue from this well-documented cohort and provides a
resource to identify prognostic and predictive biomarkers for novel
treatments.
Tumour hypoxia can drive metastasis (Sullivan and Graham,
2007) and has been associated with risk of distant metastasis in STS
(Brizel et al, 1996). This is an attractive feature of tumour biology
to manipulate, as it can be present across multiple subtypes despite
molecular heterogeneity and there are multiple drugs in existence
that can target hypoxic cell populations (Wilson and Hay, 2011).
Some of these can reduce lung metastases in preclinical models in
the adjuvant/neoadjuvant setting (Lunt et al, 2010; Liapis et al,
2015). A robust biomarker of tumour hypoxia in STS could
potentially identify around half of patients within the current high-
risk group who may benefit from hypoxia targeted therapy. Direct
measurement of hypoxia using electrodes is impractical and
imaging methods are unproven and not used in routine clinical
practice (Hammond et al, 2014; Fleming et al, 2015). Previous
studies exploring the link between endogenous hypoxia markers
(proteins known to be expressed under hypoxia) have yielded
conflicting results (Måseide et al, 2004; Shintani et al, 2006; Hoki
et al, 2007; Huang et al, 2010; Smeland et al, 2012; Kim et al, 2015)
and were limited by low numbers and old samples. This study
evaluates the prognostic value of the endogenous markers HIF-1a,
CAIX and GLUT1 in a large, modern (2013) phase III trial cohort
treated with current surgical and radiotherapy techniques (VorteX-
Biobank). REMARK guidelines for biomarker studies were
followed (McShane et al, 2005) and manual vs automated scoring
was compared.
MATERIALS AND METHODS
Patients and samples. Prospective samples were collected for the
VorteX Biobank from consenting adult patients with localised,
extremity soft tissue sarcoma receiving surgery with adjuvant
radiotherapy as part of the phase III randomised controlled VorteX
trial. The study had appropriate ethical approval (LREC 06/MRE/
03/3) and informed consent was obtained for sample collection and
analysis. Fresh tumour, matched normal tissue, formalin-fixed,
paraffin-embedded (FFPE) tissue and peripheral blood samples
were collected prior to radiotherapy.
Construction of tissue microarrays. Tumour areas in FFPE
material were demarcated by the VorteX trial histopathologist
(DH) and 1mm diameter cores were taken in triplicate from
different areas. A maximum of 120 cores were placed within a
single FFPE block in a standardised pattern (MTA-1; Beecher
Instruments, Silver Spring, MD, USA). Eleven tissue microarrays
(TMAs) were prepared in total.
Immunohistochemistry. Sections were prepared in duplicate
from each TMA for staining for a marker of interest and matched
negative control. Positive controls included FFPE sections of
hypoxic and normoxic cell pellets and tissue sections from other
tumours that had shown high or low expression of the markers in
previous experiments (Hunter et al, 2014). Tumour capillary
staining was used as an additional internal control for GLUT1
staining.
Hypoxia-inducible factor-1a and CAIX staining was performed
using the Bond-Max Automated staining system (Leica Biosystems,
Milton Keynes, UK). Slides were dewaxed and rehydrated before
antigen retrieval at pH 9.0 for 40min at 100 1C. Three per cent
hydrogen peroxide solution was used to block endogenous
peroxidases. For HIF-1a the primary antibody was mouse
monoclonal HIF-1a (BD Biosciences, Oxford, UK; 610959) (1 : 50
dilution) and the negative control was mouse IgG1 (Dako, Ely, UK;
X0931). For CAIX the primary antibody was mouse monoclonal
NCL-L-CAIX (Novacastra, Leica Biosystems, Milton Keynes, UK)
(1 : 100 dilution) and the negative control was mouse IgG2a (Dako;
X0943). All dilutions were in antibody diluent (Leica; AR9352) and
negative controls were diluted to the same protein concentration as
the primary. Slides were incubated for 8min at room temperature
with postprimary rabbit anti-mouse link reagent (Bond Polymer
Refine Detection System; Leica; DS9800) and then for a further
8min with anti-rabbit polymer-HRP detection reagent (Bond
Polymer Refine Detection System; Leica). 3,30-Diaminobenzidine
tetrahydrochloride was applied for 10min at room temperature.
Slides were then counterstained with haematoxylin.
Glucose transporter 1 staining was performed manually. Slides
were dewaxed and rehydrated. Three per cent hydrogen peroxide
solution was used to block endogenous peroxidase activity and
casein (Vector, Peterborough, UK; SP5020) was used as a protein
block. Primary antibody (rabbit polyclonal anti-GLUT1; Alpha
Diagnostic International, Source Bioscience, Nottingham, UK; GT-
12A 10 mgml 1) or negative control (rabbit IgG Vector I-1000
10 mgml 1) was incubated with the slides for 1 h at 37 1C. Slides
were then incubated with secondary antibody (Rabbit Envision
Plus HRP Kit; Dako; K4010) for 30min at room temperature.
DABþ (20 ml chromogen to 1ml substrate) was applied for 5min
at room temperature. Slides were counterstained with haematox-
ylin for 1min.
Manual scoring of immunohistochemistry markers. Slides were
viewed using Leica SCN400 Image Viewer and scored at  8
magnification. The percentage of tumour cells per core expressing
each marker was determined. Intensity was recorded for potential
future use, but was not used in the current analysis in favour of a
simpler scoring system. Negative controls were available for
comparison. For HIF-1a only nuclear staining was considered,
for CAIX only membrane staining was scored and for GLUT1
membrane and cytoplasmic staining were included.
Cores were scored twice by the same scorer (LF) on different
days. For HIF-1a and GLUT1 all cores were also scored by a
specialist sarcoma consultant histopathologist (SS) and for CAIX
this was done for all cores with staining present (PS). Scorers were
blinded to clinical outcomes. The score of the consultant
histopathologist was taken if scores were discordant. The final
score was an average across all cores for each tumour type.
Definitions of marker positivity were selected to reflect those used
in previous publications.
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Automated image analysis for scoring of immunohistochemistry
markers. Tissue microarray images were imported into Definiens
tissue studio v.4.2 (Definiens, Munich, Germany) and each core
labelled with a coordinate according to location. Scoring
algorithms were generated and iteratively improved for each
marker with quantifiably expressed instructions for tissue detec-
tion, nuclear detection, cell stimulation and scoring thresholds
(Supplementary Figure 1).
Statistical analysis. The trial primary outcome measures were
limb functionality and time to local recurrence, whereas secondary
outcomes were disease-free survival (DFS) and overall survival
(OS). The clinical outcome measure for the prognostic analysis was
DFS, defined as the time from randomisation to local recurrence,
metastasis or death. Patients without a DFS event were censored at
the date last known to be alive and event free. Estimates were
calculated using Kaplan–Meier (KM) analysis. The log-rank test
was used to determine any difference in the outcome for each
biomarker split combination. Hazard ratios (HRs) and 95%
confidence intervals (CIs) were obtained using Cox regression
analysis (univariable and multivariable). Univariable Cox model-
ling was used to identify clinicopathologic factors correlated to
DFS in this cohort including grade, size (combined as stage), depth,
gender, surgical margin, tumour location (upper or lower limb),
WHO performance status and age. Factors significant at the 5%
level in the univariable analysis were included in multivariable
analyses with each of the study biomarkers. Spearman’s correlation
and Bland–Altman (Bland and Altman, 1986) plots were used to
assess intra- and interobserver variability for duplicate and
independent scores per core and to compare manual and
automated scores per core. Analysis was performed using Stata
v.14 (College Station, TX, USA).
RESULTS
Available material. Between 2007 and 2013, 319 patients were
registered. Of these, 216 patients met the eligibility criteria and
were randomised between two different volumes of adjuvant
radiotherapy. At the time of analysis median follow-up using
reverse KM methodology was 5.2 years and event rates were 12%
(25 out of 216) and 40% (86 out of 216) for local recurrence and
any DFS event, respectively. Two hundred and three of 216
randomised patients (with complete clinical outcome data)
consented to the VorteX-Biobank. Table 1 summarises the baseline
characteristics in the Biobank population. Tissue collected is
summarised in Supplementary Table 1. Staining results and clinical
outcome data were available for 165, 183 and 179 patients for HIF-
1a, CAIX and GLUT1, respectively (Figure 1). A scoring result was
not available for every patient due to TMA degradation, lack of
tumour in core or poor image quality.
Protein marker expression. Supplementary Figure 2 shows
staining patterns for the three markers. Hypoxia-inducible
factor-1a staining was clearly nuclear and CAIX clearly membra-
nous, consistent with the expected location for activity of these
proteins. Very little additional staining was seen for these markers
when compared to the negative control. GLUT1 staining was
membranous and cytoplasmic, both were scored as a GLUT1 score
based on both membranous and cytoplasmic staining has
previously been shown to correlate with oxygen electrode
measurements in cervix cancer (Airley et al, 2001). Results and
thresholds defining positivity for each marker are included in
Supplementary Table 2. The median of all scores was zero for all
three markers; therefore, cores with any staining present were
considered positive. The median of all results greater than zero was
used to define strong positive. Duplicate and independent scores
per core correlated well (Spearman’s r40.8) and Bland–Altman
analyses comparing scores are included in Supplementary Table
and Supplementary Figure 5. There was poor overlap for positivity
for markers within the same tumour sample (Supplementary
Figure 4).
Prognostic significance. Grade and size (combined as stage) and
depth were significant in univariable analyses (Table 2) and
incorporated in the multivariable analysis. Gender, surgical
margin, tumour location (upper or lower limb), WHO perfor-
mance status and age were not prognostic in the univariable
analysis.
Kaplan–Meier survival estimates for HIF-1a, CAIX and GLUT1
are presented in Figure 2. The P-value reported on the figures is
from the log-rank test. When patients were split into two groups
based on HIF-1a positivity (median split or 410% stained), there
was no statistically significant difference in DFS (HR 1.41, 95% CI:
0.86, 2.31, P¼ 0.174 for median split, HR 1.66, 95% CI: 0.98, 2.81,
P¼ 0.058 for 410% stained). When patients were split into three
groups (strong positive, weak positive, negative) strong positive vs
negative staining was associated with worse DFS (HR 1.76, 95% CI:
1.01, 3.07, P¼ 0.048). This was not significant on multivariable
analysis (HR 1.31, 95% CI: 0.74, 2.32, P¼ 0.348).
Carbonic anhydrase IX was the strongest prognostic marker and
was the only marker to retain prognostic significance in any of the
multivariable analysis. Poor DFS was associated with CAIX values
Table 1. Baseline characteristics
n¼203 %¼100
Age
Median 60 years, interquartile range 48–69 years
Gender
Male 121 60
Female 82 40
WHO performance status
0–1 163 80
2–3 5 2
Unknown 35 18
Grade
1 14 7
2 39 19
3 150 74
Depth
Superficial 36 18
Deep 166 82
Unknown 1 0
Size
T1 (p5 cm) 19 9
T2 (45 cm) 184 91
Surgical margin
Intralesional 5 2
Marginal 79 39
Wide 119 59
Histologic subtype
Dedifferentiated liposarcoma 5 2
Extraskeletal myxoid chrondrosarcoma 4 2
Leiomyosarcoma 9 4
Malignant peripheral nerve sheath tumour 6 3
Malignant solitary fibrous tumour 4 2
Myxofibrosarcoma 52 26
Myxoid liposarcoma 27 13
Pleomorphic liposarcoma 5 2
Pleomorphic rhabdomyosarcoma 3 1
Synovial sarcoma 6 3
Undifferentiated pleomorphic sarcoma 68 33
Other 13 6
Unknown 1 0
Abbreviation: WHO¼World Health Organisation.
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above the median (HR 2.28, 95% CI: 1.44, 3.59, Po0.001) or
410% stained (HR 1.75, 95% CI: 1.04, 2.94, P¼ 0.037). These
estimates remained significant for the median split in the
multivariable analyses (HR 2.04, 95% CI: 1.29, 3.25, P¼ 0.002),
but not at the 410% stained split (HR 1.60, 95%CI: 0.95, 2.71,
P¼ 0.078). There was no observable difference between strong and
weak positive values for CAIX with both being graphically
comparable (Figure 2f). There was no difference in baseline
characteristics between CAIX-positive and -negative patients
(Supplementary Table 4).
Glucose transporter 1 was not prognostic (HR 1.10, 95% CI:
0.69, 1.73, P¼ 0.695 – median split, HR 1.36, 95% CI: 0.82, 2.26,
P¼ 0.232 – 410% stained, HR 1.39, 95% CI: 0.80, 2.41, P¼ 0.238
– strong positive vs negative).
Comparison of manual and automated scoring. Most cores were
successfully scored by automated analysis. Cores were excluded if
there was insufficient tissue or core quality was poor. Correlation
between manual and automated scores was relatively poor
(Spearman’s ro0.72) and Bland–Altman analyses comparing
scores are included in Supplementary Table and Supplementary
Figure 5. KM survival estimates for HIF-1a and CAIX automated
scores are shown in Supplementary Figure 6.
DISCUSSION
Owing to its rarity and heterogeneity, acquiring adequately sized
cohorts of STS patients with both high-quality tumour tissue and
robust clinical outcome data is extremely challenging. VorteX is the
largest adjuvant radiotherapy trial completed in STS and provides a
substantial cohort of patients with high-risk, localised disease
covering a range of the more common subtypes seen in adults. The
VorteX-Biobank was successful in collecting a wide range of tissue
from these patients including FFPE tissue from 301 (94%) of
enrolled patients and 203 (98%) of randomised patients and
matched tumour and normal tissue from 190 (88%) of randomised
patients. This has created a valuable resource for the study of STS
biology and identification and validation of biomarkers for novel
treatment strategies and highlights the importance of tissue
banking alongside clinical trials whenever possible for rare cancers.
Staining patterns for endogenous immunohistochemistry mar-
kers of tumour hypoxia were consistent with previous studies in
STS (Kim et al, 2015) and other cancers (Airley et al, 2003; Hunter
et al, 2014). Spearman’s correlation for duplicate and independent
scores was high. However, Bland–Altman analyses revealed that
while the mean difference between scores was low between
independent scores for all markers, the upper and lower limits of
agreement were relatively high for CAIX ( 28.9, 15.3) and
GLUT1 ( 19.7, 16.1) (Supplementary Figure 3). For CAIX this
can be attributed to the fact that only positive cores were second
scored for this marker, as due to the quality of the antibody and the
staining pattern it was clear if a core was negative. As the optimal
definition of positive for CAIX was the presence of any staining, a
difference in scores between observers would not alter the
classification of the sample if it was used as a biomarker. Although
automated scoring would reduce analysis time and the need for
specialist pathology input, this was not comparable to manual
scoring by a sarcoma pathologist. Correlation between scores and
Bland–Altman bias were not within acceptable limits
(Supplementary Table and Supplementary Figure 5) and when
KM analyses were performed for HIF-1a and CAIX using
automated scores neither were found to be prognostic
(Supplementary Figure 6). This is probably due to difficulty in
using the software to define regions of stained tumour cells vs
stroma or artefact.
Registered patients n = 319
No tissue received for VBB n = 21
FFPE tissue n = 298
Not randomised (no clinical outcome data) n = 95
Randomised patients n = 203
Failed core
n = 38
Failed core
n = 20
Failed core
n = 24
GLUT1 result
n = 179
CAIX result
n = 183
HIF-1 result
n = 165
Figure 1. CONSORT diagram. Data for HIF-1a, CAIX and GLUT1
expression were available for 165, 183 and 179 patients randomised in
the VorteX trial, respectively. CAIX¼ carbonic anhydrase IX;
FFPE=formalin-fixed, paraffin-embedded; HIF-1a¼hypoxia-inducible
factor-1a; GLUT1¼glucose transporter 1; VBB¼VorteX-Biobank.
Table 2. Univariable analyses
HR (95% CI) P-value
Age
1.00 (0.99, 1.02) 0.616
Gender
Female 1 —
Male 1.18 (0.76, 1.86) 0.460
WHO performance status
0 1
1 1.43 (0.83, 2.48) 0.202
2 1.37 (0.33, 5.65) 0.661
Stage (grade, size)
I 0.46 (0.17, 1.26) 0.131
II 0.29 (0.15, 0.59) 0.001
III 1 —
Depth
Deep 1 —
Superficial 0.46 (0.22, 0.95) 0.037
Surgical margin
Wide 1 —
Intralesional 1.15 (0.28, 4.75) 0.846
Marginal 1.19 (0.77, 1.85) 0.439
Location
Lower limb 1 —
Upper limb 0.96 (0.77, 1.85) 0.898
HIF-1a (median split)
Negative 1 —
Positive 1.41 (0.86, 2.31) 0.174
CAIX (median split)
Negative 1 —
Positive 2.28 (1.44, 3.59) o0.001
GLUT1 (median split)
Negative 1 —
Positive 1.10 (0.69, 1.73) 0.695
Abbreviations: CAIX¼ carbonic anhydrase IX; CI¼ confidence interval; HIF-1a¼ hypoxia-
inducible factor-1a; HR¼ hazard ratio; GLUT1¼glucose transporter 1.
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Thresholds for marker positivity were selected to make results
comparable with previously published studies. For HIF-1a this was
difficult as previous studies have varied widely from considering
410% staining of any intensity as positive (Huang et al, 2010), to
defining only tumours with over 50% of cells strongly stained as
positive (Smeland et al, 2012). In the current work, intensity of
staining was recorded for potential future use but was not
considered at present as a simpler scoring system is likely to be
more easily reproducible. For the CAIX studies evaluating
membrane staining, one has used a cutoff value of 10% stained
(Kim et al, 2015), and another has defined any staining as positive
as it demonstrated no difference in outcome between patients
classified as strongly or weakly positive (Måseide et al, 2004). This
is consistent with the current work.
Hypoxia-inducible factor-1a and CAIX expression are asso-
ciated with worse DFS, albeit CAIX was the only hypoxia marker
that was significant in the multivariable analysis. Glucose
transporter 1 was not prognostic. Four of five previous studies
(Shintani et al, 2006; Hoki et al, 2007; Huang et al, 2010; Smeland
et al, 2012; Kim et al, 2015) have associated high HIF-1a
expression with adverse outcomes. Two of three previous studies
(Måseide et al, 2004; Smeland et al, 2012; Kim et al, 2015) have
associated high CAIX expression with poor outcomes in STS, and
high GLUT1 expression has been shown to correlate with worse
outcomes in one of two prior studies (Smeland et al, 2012; Kim
et al, 2015). Results of the largest previous study (Smeland et al,
2012) (B200 patients) were almost opposite to the current work
with no association for HIF-1a and CAIX, but prognostic value
reported for GLUT1. This may be explained by the fact that the
previous study reported different staining patterns that would be
considered unusual for the markers in question (mainly cytoplas-
mic for all markers) and included relatively old samples. The
staining patterns scored in the current work are more consistent
with the expected location of the active proteins and the cohort is
superior to those used in previous studies, as this is a modern
phase III trial population (2007–2013) with recent tissue collection
and robust outcome data.
Although the current work did not find HIF-1a staining to be
prognostic, it may potentially still be of interest. A recent meta-
analysis of 16 studies (5 in STS) evaluating the prognostic
HIF-1 CAIX GLUT1
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Figure 2. Kaplan–Meier survival estimates for HIF-1a (A–C), CAIX (D–F) and GLUT1 (G–I). (A) HIF-1a-positive vs –negative, (B) HIF-1a p10% vs
410%, (C) HIF-1a strong positive, weak positive, negative, (D) CAIX positive vs negative, (E) CAIXp10% vs410%, (F) CAIX strong positive, weak
positive, negative, (G) GLUT1 positive vs negative, (H) GLUT1 p10% vs 410% and (I) GLUT1 strong positive, weak positive, negative.
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significance of HIF-1a in STS and bone sarcomas found high
expression was associated with higher rates of metastases, poor OS
and poor DFS (Li et al, 2016). A consistent association with poor DFS
was found in the STS subgroup analysis, although this only considered
136 patients in three studies. A limitation of HIF-1a is that it is more
difficult to score and define positivity than for CAIX, which can
simply be classed as positive in the presence of any membrane
staining. Based on this work, CAIX appears to be the best current
known hypoxia marker for use on pretreatment biopsies in STS.
Tissue microarrays rather than whole sections were used for this
study due to the large number of samples. This is a potential
limitation of the work as it assesses a smaller area than a whole
section and therefore may be more likely to misclassify a hypoxic
tumour as normoxic. However, this was assessed in one of the
previous studies of CAIX in STS and TMAs were deemed accurate
in determining marker expression provided that at least three cores
were taken from two separate areas of tumour (Måseide et al,
2008). Another concern was that there was very limited overlap
between expression of the markers in these clinical samples. All
three markers are expressed under hypoxia and a degree of
coexpression was expected. This may reflect the considerable
molecular heterogeneity of STS and indicates that expression of
these markers is likely influenced by other pathways. There is
therefore a need for a more robust measure of hypoxia in STS than
a single protein marker.
Hypoxia-related RNA expression signatures measure changes in
multiple genes in response to hypoxia and can account for greater
heterogeneity (Harris et al, 2015). Evaluation of a biomarker at the
RNA level also reduces inconsistencies in methodology and
interpretation between laboratories compared with IHC and is
more likely to be reproducible in clinical practice. Hypoxia RNA
expression signatures have made the most progress towards use as
predictive biomarkers for hypoxia targeted therapy in the clinic,
with two signatures (Toustrup et al, 2012; Eustace et al, 2013)
currently undergoing prospective validation in phase III trials in
head and neck cancer. Recently, one of these signatures has
demonstrated prognostic value in a cohort of STS patients
(Aggerholm-Pedersen et al, 2016). However, hypoxia signatures
generally perform best in the tumour types they were developed for
(Eustace et al, 2013) and the signature genes correlated poorly with
oxygen electrode measurements in 16 patients indicating that it
may not be a good measure of hypoxia in STS (Aggerholm-Pedersen
et al, 2016). It may be more appropriate to derive a hypoxia signature
specific to STS, as it must be a robust measure of hypoxia if it is to be
used as a predictive biomarker for hypoxia targeted therapy. The
other tissue available in the VorteX-Biobank is intended to be used
for this purpose with the eventual aim of a biomarker-driven trial of
hypoxia targeted adjuvant/neoadjuvant therapy in STS.
In summary, evaluation of protein hypoxia markers in a modern
phase III clinical trial cohort suggests that CAIX is the best current
known hypoxia marker. A simple binary scoring system can easily
be implemented to define positivity but still requires manual
pathology assessment. However, other measures of hypoxia such as
gene signatures may perform better and be more reflective of
hypoxia across different subtypes, compensating for greater
heterogeneity. Further work is needed to develop a gene signature
and confirm that it is a true measure of hypoxia by comparing this
to CAIX and other methods of assessing hypoxia (e.g. imaging/
electrodes) before this could be taken forward as a prognostic or
predictive biomarker for clinical trials.
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